Quinz advised Ampersand Capital on its investment. P95 BV, a global provider of epidemiology and clinical research solutions focused on vaccines and infectious diseases, has announced...
Ampersand Capital’s Investment in P95
Ampersand Capital Partners’ $1.2 Billion Closing of Latest Fund
Goodwin Procter advised Ampersand Capital Partners on the deal. Ampersand Capital Partners announced its first and only closing of Ampersand 2022 Limited Partnership with $1.2 billion in...
Ampersand Capital Partners’ Acquisition of a Minority Stake in BioEcho Life Sciences
McDermott Will & Emery and Pier11 advised Ampersand Capital Partners on the deal. Ampersand Capital Partners announced the acquisition of a minority stake in BioEcho Life...
Vivitide’s Business Combination With Biosynth Carbosynth
McDermott Will & Emery represented Ampersand Capital Partners in the transaction. Ampersand Capital Partners, a healthcare-focused private equity fund, and KKR, a leading global investment firm, finalized...